Related references
Note: Only part of the references are listed.Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the Cardiac Benefits of Empagliflozin Independent of its Hypoglycemic Activity?
Carlos G. Santos-Gallego et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
Dustin M. Lee et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Eduardo Flores et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Alvaro Garcia-Ropero et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training
Andreas B. Gevaert et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
Robert Chilton et al.
DIABETES OBESITY & METABOLISM (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Gian Paolo Fadini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Michael Joubert et al.
DIABETES (2017)
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
Michael Pfeifer et al.
CARDIOVASCULAR DIABETOLOGY (2017)
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Christian Ott et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
A new porcine model of hypertensive cardiomyopathy: a helpful tool to explore the HFpEF mystique
Kai Hu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction
Michael Schwarzl et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Invasive Hemodynamic Characterization of Heart Failure with Preserved Ejection Fraction
Mads J. Andersen et al.
HEART FAILURE CLINICS (2014)
H2S Protects Against Pressure Overload-Induced Heart Failure via Upregulation of Endothelial Nitric Oxide Synthase
Kazuhisa Kondo et al.
CIRCULATION (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation
Walter J. Paulus et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Vasodilatory Effects of Cinnamic Acid via the Nitric OxidecGMPPKG Pathway in Rat Thoracic Aorta
Yun Hwan Kang et al.
PHYTOTHERAPY RESEARCH (2013)
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Barry A. Borlaug et al.
EUROPEAN HEART JOURNAL (2011)
Relationship between renal function and heart failure in hypertensive patients
M. Luque et al.
INTERNAL MEDICINE JOURNAL (2010)
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction A Community-Based Study
Carolyn S. P. Lam et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Role of left ventricular stiffness in heart failure with normal ejection fraction
Dirk Westermann et al.
CIRCULATION (2008)
Prognostic importance of pulmonary hypertension in patients with heart failure
Jesper Kjaergaard et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Outcome of heart failure with preserved ejection fraction in a population-based study
R. Sacha Bhatia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Heart failure with preserved left ventricular Systolic function - Epidemiology clinical characteristics and prognosis
K Hogg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Diastolic heart failure - Abnormalities in active relaxation and passive stiffness of the left ventricle
MR Zile et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Doppler-derived dP/dt and -dP/dt predict survival in congestive heart failure
TJ Kolias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
